Cancer-Killing Virus Acts by Alerting Immune System
A collaboration between SillaJen Biotherapeutics researchers and the McDonald Lab at the University of California San Francisco highlights the potential for combination therapy using oncolytic viruses and immunotherapy.
Combination trials with Pexa-Vec and immune checkpoint inhibitors
· First-line Treatment of Advanced Hepatocellular Carcinoma (HCC) NCT03071094
· Refractory Colorectal Cancer NCT03206073
· Renal Cell Carcinoma NCT03294083